A Case of Dermatomyositis with Coexistence of Positive Anti-MDA5 Antibodies and Anti-SSA/RO52 Antibodies, Combined with Necrotic Skin Ulcers

References

• Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55. doi:10.1016/j.jaut.2019.04.001
   PubMed Web of Science ®Google Scholar
• Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021;12:773352. doi:10.3389/fimmu.2021.773352
   PubMed Web of Science ®Google Scholar
• Yang J, Yan B. Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: time to nip them in the bud. Front Immunol. 2022;13:1009546. doi:10.3389/fimmu.2022.1009546
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis. Ann Transl Med. 2017;5(7):160. doi:10.21037/atm.2017.03.94
   PubMed Web of Science ®Google Scholar
• Li J, Liu Y, Li Y, et al. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis. J Dermatol. 2018;45(1):46–52. doi:10.1111/1346-8138.14092
   PubMed Web of Science ®Google Scholar
• Keppeke GD, Satoh M, Kayser C, et al. A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol. 2022;13:1011110. doi:10.3389/fimmu.2022.1011110
   PubMed Web of Science ®Google Scholar
• Coutant F, Bachet R, Pin JJ, Alonzo M, Miossec P. Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. J Autoimmun. 2022;130:102831. doi:10.1016/j.jaut.2022.102831
   PubMed Web of Science ®Google Scholar
• Gui X, Shenyun S, Ding H, et al. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford). 2022;61(11):4570–4578. doi:10.1093/rheumatology/keac090
   PubMed Web of Science ®Google Scholar
• Castellanos-Gonzalez M, Bris BB, Marsol IB, et al. Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study. J Dtsch Dermatol Ges. 2023;21(7):741–748. doi:10.1111/ddg.15089
   Web of Science ®Google Scholar
• Cox NH, Coulson JH. Diagnosis of skin disease. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. Vol. 1. Hoboken: Blackwell Publishing Ltd; 2010.
   Google Scholar
• Fernandez-Flores A, Cassarino DS. Gottron Papules Show Histopathologic Features of Localized Lymphedema. Am J Dermatopathol. 2017;39(7):518–523. doi:10.1097/DAD.0000000000000701
   PubMed Web of Science ®Google Scholar
• Thuner J, Coutant F. IFN-γ: an overlooked cytokine in dermatomyositis with anti-MDA5 antibodies. Autoimmun Rev. 2023;22(10):103420. doi:10.1016/j.autrev.2023.103420
   PubMed Web of Science ®Google Scholar
• Hu H, Yang H, Liu Y, Yan B. Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: a Concise Review With an Emphasis on Type I Interferon System. Front Med Lausanne. 2022;8:833114. doi:10.3389/fmed.2021.833114
   PubMed Web of Science ®Google Scholar
• Cao H, Xia Q, Pan M, et al. Gottron Papules and Gottron Sign with Ulceration: a Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis. J Rheumatol. 2016;43(9):1735–1742. doi:10.3899/jrheum.160024
   PubMed Web of Science ®Google Scholar
• Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776–785. doi:10.1016/j.jaad.2017.12.010
   PubMed Web of Science ®Google Scholar
• Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken). 2015;67(5):667–672. doi:10.1002/acr.22498
   PubMed Web of Science ®Google Scholar
• Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395–402. doi:10.1111/bjd.14882
   PubMed Web of Science ®Google Scholar
• Xu A, Ye Y, Fu Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021;60(7):3343–3351. doi:10.1093/rheumatology/keaa786
   PubMed Web of Science ®Google Scholar
• Wang H, Chen X, Du Y, et al. Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. Arthritis Res Ther. 2023;25(1):127. doi:10.1186/s13075-023-03100-z
   PubMed Web of Science ®Google Scholar
• Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283–296. doi:10.1016/j.jaad.2019.05.105
   PubMed Web of Science ®Google Scholar
• You H, Wang L, Wang J, et al. Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China. Rheumatology (Oxford). 2023;62(3):1216–1226. doi:10.1093/rheumatology/keac450
   PubMed Web of Science ®Google Scholar
• Tsuji H, Nakashima R, Hosono Y, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020;72(3):488–498. doi:10.1002/art.41105
   PubMed Web of Science ®Google Scholar
• Huang K, Vinik O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019;39(11):1971–1981. doi:10.1007/s00296-019-04398-2
   PubMed Web of Science ®Google Scholar
• Nishi K, Ogura M, Tamai N, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J. 2022;20(1):60. doi:10.1186/s12969-022-00723-5
   PubMed Web of Science ®Google Scholar
• Yen TH, Tseng CW, Wang KL, Fu PK. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: a Case Report. Medicina. 2021;57(12):1358. doi:10.3390/medicina57121358
   PubMedGoogle Scholar
• Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27(3):536–540. doi:10.3109/14397595.2015.1014140
   PubMed Web of Science ®Google Scholar
• Collantes-Rodríguez C, Jiménez-Gallo D, Ossorio-García L, Villegas-Romero I, Linares-Barrios M. Image Gallery: cutaneous ulcers in anti-MDA5 dermatomyositis successfully treated with sildenafil. Br J Dermatol. 2020;182(1):e1. doi:10.1111/bjd.18376
   PubMed Web of Science ®Google Scholar
• Gu Q, Diao M, Hu W, Huang M, Zhu Y. Case Report: extracorporeal Membrane Oxgenation for Rapidly Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis in a Post-partum Woman. Front Med Lausanne. 2021;8:742823. doi:10.3389/fmed.2021.742823
   PubMed Web of Science ®Google Scholar